Clinical Trials on Thrombocytopenia in New Zealand

Total 155 results

GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
Amgen

Completed

Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura

United States, Canada, Australia
Pfizer

Terminated

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

Healthy | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Primary Immune Thrombocytopenia

Spain, United States, Belgium, United Kingdom, New Zealand
GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

Purpura, Thrombocytopaenic, Idiopathic

United States
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Thailand, Korea, Republic of, United Kingdom, New Zealand, Germany, Greece, Hong Kong, Pakistan, Poland, Romania, Russian Federation, Slovenia, Taiwan
Eisai Inc.

Completed

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

Immune Thrombocytopenia | Chronic Thrombocytopenia

Poland, Ukraine, Belgium, Bulgaria, South Africa, Netherlands, New Zealand, Singapore, Australia, Slovakia, Czechia
GlaxoSmithKline

Completed

Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (PETIT)

Purpura, Thrombocytopaenic, Idiopathic

United States, France, Netherlands, Spain, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

EXTEND (Eltrombopag Extended Dosing Study) (EXTEND)

Purpura, Thrombocytopaenic, Idiopathic

United Kingdom, Hong Kong, United States, Germany, Italy, Netherlands, Spain, Taiwan, Thailand, Canada, Denmark, Pakistan, Romania, Slovenia, Russian Federation, Slovakia, Sweden, Poland, China, New Zealand, Ukraine, Australia, Austria and more
GlaxoSmithKline

Completed

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag (RAISE)

Purpura, Thrombocytopaenic, Idiopathic

United States, Taiwan, Italy, Poland, Peru, Canada, Denmark, Germany, Slovakia, Spain, United Kingdom, New Zealand, China, Greece, Hong Kong, Russian Federation, Austria, Netherlands, Czech Republic, France, India, Ukraine, Tunisia, F... and more
Weill Medical College of Cornell University

Terminated

A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone (Dex/Rituxan)

Idiopathic Thrombocytopenia Purpura

United States
Amgen

Completed

A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura

Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP

United States, Canada, Australia, Spain
Shionogi

Terminated

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia (ITP)

United States
Weill Medical College of Cornell University
Children's Hospital of Orange County

Completed

A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013

Immune Thrombocytopenia

United States
Weill Medical College of Cornell University
GlaxoSmithKline

Completed

Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenia

United States
Weill Medical College of Cornell University
Novartis

Terminated

End of EXTEND: Discontinuation of Medication for Patients With Immune Thrombocytopenia

Immune Thrombocytopenia

United States
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura

United States
GlaxoSmithKline

Completed

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopaenic, Idiopathic

Italy, Germany, Hong Kong, Korea, Republic of, United States, Pakistan, Russian Federation, India, Czech Republic, Hungary, France
Stanford University
Weill Medical College of Cornell University

Completed

Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics

Immune Thrombocytopenia

United States
GlaxoSmithKline

Completed

LENS - Long-term Eltrombopag Observational Study (LENS)

Purpura, Thrombocytopaenic, Idiopathic

United States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
Principia Biopharma, a Sanofi Company

Active, not recruiting

A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia | Immune Thrombocytopenic Purpura

United States, Australia, Bulgaria, Canada, Czechia, Netherlands, Norway, United Kingdom
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Pfizer

Recruiting

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

United States, Australia, Canada, Czechia, Poland, Hungary, United Kingdom
Weill Medical College of Cornell University
Novartis

Completed

Safety and Efficacy of Eltrombopag at Escalated Doses

Immune Thrombocytopenia | Platelet Disorder

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Thrombocytopaenia

United States, Germany, Israel, Belgium, Finland, Ireland, Italy, Greece, India, Czech Republic, Hungary, Canada, Poland
Icahn School of Medicine at Mount Sinai
Beth Israel Medical Center

Terminated

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (TTP)

Thrombotic Thrombocytopenic Purpura

United States
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
Weill Medical College of Cornell University
Genentech, Inc.; Biogen

Completed

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

United States
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
Octapharma

Terminated

Octaplas Adult TTP Trial

Thrombotic Thrombocytopenic Purpura

United States
Novartis Pharmaceuticals

Recruiting

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) (VAYHIT1)

Primary Immune Thrombocytopenia (ITP)

China, United States, Spain, Singapore, Austria, Germany, Belgium, Italy, Japan, Czechia, Hong Kong, Hungary, Malaysia, Argentina, Bulgaria, Turkey, Vietnam, Australia, Thailand, Mexico, United Kingdom, France, Romania, Norway, India
Beth Israel Medical Center

Completed

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

Immune Thrombocytopenia | Myelodysplasia | Chemotherapy Induced Thrombocytopenia | Aplastic Anaemia

United States
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Gilead Sciences

Terminated

Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Purpura, Thrombocytopenic, Idiopathic | Autoimmune Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Autoimmune

United States
Eisai Inc.

Completed

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Idiopathic Thrombocytopenic Purpura

United States
Shionogi

Terminated

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia

United States
GlaxoSmithKline

Completed

SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

Thrombocytopaenia

Spain, Taiwan, Bulgaria, United States, Argentina, Russian Federation, Germany, Korea, Republic of, Austria, India, Italy, United Kingdom, Poland, Romania, Ukraine, Hungary, Peru, Czech Republic, Mexico
New York Medical College

Recruiting

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura (NYMC207)

Immune Thrombocytopenic Purpura

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, Argentina, Australia, United Kingdom, Poland, United States
Rigel Pharmaceuticals

Terminated

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Immune Thrombocytopenia | ITP

United States
GlaxoSmithKline

Completed

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

Immune Thrombocytopenic Purpura

United States
Rigel Pharmaceuticals

Completed

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Purpura, Thrombocytopenic, Idiopathic

United States
Bristol-Myers Squibb

Completed

Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Georgia, Moldova, Republic of, Poland, Russian Federation
Boston Children's Hospital
Baylor College of Medicine; Children's Hospital of Philadelphia; Columbia University and other collaborators

Completed

Association of Platelet Parameters With Bleeding Severity in Children With ITP (ITP-APPS)

Immune Thrombocytopenia

United States
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
Genzyme, a Sanofi Company

Terminated

Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura

United States
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.

Terminated

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP) (STAR)

Thrombotic Thrombocytopenic Purpura

United States
Protalex, Inc.

Terminated

PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP

Immune Thrombocytopenia

United States, United Kingdom

Clinical Trials on Thrombocytopenia in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations